Mass Spectrometry Provides a Highly Sensitive Noninvasive Means of Sequencing and Tracking M-Protein in the Blood of Multiple Myeloma Patients
The amino acid sequence of the M-protein for multiple myeloma is unique compared to the polyclonal antibodies in patients’ blood. This publication from Rapid Novor describes a targeted MS/MS assay to detect and quantify the unique M-protein sequence in serum samples...EasyM – A personalized MS-based assay to monitor multiple 2 myeloma disease assessment facilitated by the Evosep One
This publication by the Trudel group describes the development of a non-invasive MS-based assay, called EasyM, which is used to assess minimal residual disease, a measure of depth of remission to treatment, which has become an important parameter in assessing the disease burden in multiple myeloma.
